Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 11/20 | 0.60 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16430875 | 0.86 | MAPT (0.58) | SLC6A4SLC6A2SLC6A3POLBMEN1 | |
| SCHEMBL30610315 | 0.86 | MAPT (0.58) | SLC6A4SLC6A2SLC6A3POLBMEN1 | |
| SCHEMBL1340717 | 0.86 | SLC6A2 (0.70) | PDE7ASLC6A4SLC6A2SLC6A3POLB | |
| SCHEMBL17080230 | 0.85 | SLC6A4 (0.56) | PDE7ASLC6A4SLC6A2SLC6A3POLB | |
| SCHEMBL4637170 | 0.85 | SLC6A4 (0.56) | PDE7APDE7BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3838973 | 0.85 | SLC6A4 (0.56) | PDE7APDE7BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4636875 | 0.85 | PDE7A (0.66) | PDE7APDE7BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17862100 | 0.84 | MAPT (0.67) | PDE7ASLC6A4SLC6A2SLC6A3POLB | |
| SCHEMBL28230963 | 0.84 | LMNA (0.57) | SLC6A4SLC6A2SLC6A3POLBMEN1 | |
| SCHEMBL18666983 | 0.82 | SLC6A4 (0.52) | PDE7ASLC6A4SLC6A2SLC6A3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-8927544-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927544-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927544-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2013130958-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-5798350-A | TRICYCLIC DIBENZ(B,F)OXEPINES AND DIBENZO(B,F)THIEPINES FOR TREATING SCHIZOPHRENIA AND ANXIETY | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1998-08-25 | — | — | US | disclosed |
| US-5703072-A | TREATMENT OF SCHIZOPHRENIA AND ANXIETY | ALLELIX BIOPHARMACEUTICALS (CA) | 1997-12-30 | — | — | US | disclosed |
| US-5674877-A | TREATMENT OF PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1997-10-07 | — | — | US | disclosed |
| EP-0797577-A1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | Allelix Biopharmaceuticals Inc. (CA) | 1997-10-01 | — | — | EP | disclosed |
| EP-0736024-A1 | N-HETEROBICYCLYL-PIPERAZINYL OR-PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RECEPTOR LIGANDS | Allelix Biopharmaceuticals Inc. (CA) | 1996-10-09 | — | — | EP | disclosed |
| US-5561127-A | TREATING ANXIETY, SCHIZOPHRENIA | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1996-10-01 | — | — | US | disclosed |
| US-5538965-A | TREATMENT OF PSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA AND ANXIETY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1996-07-23 | — | — | US | disclosed |
| WO-1996019479-A1 | MUSCARINIC RECEPTOR LIGANDS | ALLELIX BIOPHARMACEUTICALS INC. (US) | 1996-06-27 | — | — | WO | disclosed |
| WO-1996018630-A1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1996-06-20 | — | — | WO | disclosed |
| WO-1995017400-A1 | N-HETEROBICYCLYL-PIPERAZINYL OR-PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RECEPTOR LIGANDS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CCR5 | PDE7A 1086/4885PDE7B 1250/4885SLC6A4 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.